Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study

Basit Öğe Kaydı
dc.contributor.authorShitara, Kohei
dc.contributor.authorGumus, Mahmut
dc.contributor.authorPietrantonio, Filippo
dc.contributor.authorLonardi, Sara
dc.contributor.authorDe La Fouchardiere, Christelle
dc.contributor.authorCoutzac, Clelia
dc.contributor.authorDekervel, Jeroen
dc.date.accessioned2025-11-16T19:34:30Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipDaiichi Sankyo, Inc.
dc.description.sponsorshipDaiichi Sankyo, Inc.
dc.identifier.doi10.1200/JCO.2025.43.17_suppl.LBA4002
dc.identifier.endpageLBA4002
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue17_SUPPL
dc.identifier.startpageLBA4002
dc.identifier.urihttps://doi.org/10.1200/JCO.2025.43.17_suppl.LBA4002
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15362
dc.identifier.volume43
dc.identifier.wosWOS:001511752700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleTrastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu